January 16, 2009 -St. Jude Medical Inc. this week said a study was published on the St. Jude Medical Biocor Stented Tissue Valve with 20-year data showing excellent long-term durability of the Biocor tissue valve.

Published in the January 2009 issue of the Journal of Thoracic and Cardiovascular Surgery, this prospective study compiles data from 1,712 patients, and is one of the largest published studies of tissue valves.

January 15, 2009 - The six-month follow-up examination of a 64-year-old man enrolled in SECRITT I, a pilot study designed to evaluate the vProtect Luminal Shield as a treatment for vulnerable plaque, revealed that the target plaque was successfully stabilized.

The interventional cardiology team led by Professor Patrick W. Serruys, M.D., PhD, of Erasmus University, placed the vProtect Luminal Shield in the left anterior descending (LAD) coronary artery of the patient at Erasmus Medical Center in Rotterdam in June of 2008.

January 15, 2009 - Implantable cardioverter defibrillators (ICDs) may reduce the risk of death by 30 percent in older patients with reduced heart function, according to research reported in Circulation: Cardiovascular Quality and Outcomes.

Paul Chan, M.D., M.Sc., lead author of the study and assistant professor at the Mid-America Heart Institute and the University of Missouri in Kansas City, said that ICDs reduced the risk of dying by 30 percent in patients younger than 65 years old, 65 to 74, and 75 and older.


Is an evolution of sorts happening within advanced visualization?

January 14, 2009 - According to Millennium Research Group's (MRG's) U.S. Markets for Electrophysiology (EP) Mapping and Ablation Devices 2009 report, an increase in the number of catheter ablation procedures for treating atrial fibrillation (AF) will fuel revenues in the EP ablation catheter market over the next five years.

The ablation catheter market will exhibit strong growth from 2008 to 2013, at a compound annual rate of almost 14 percent, exceeding $480 million by the end of 2013, MRG said.

January 14, 2009 - Society of Nuclear (SNM) will devote its annual Molecular Imaging Summit to introducing the new SNM Clinical Trials Network, Feb. 8–9, at the Hilton Clearwater Hotel, Clearwater, FL.

In part, the program will explain requirements of participation in the Clinical Trials Network, which was designed to facilitate cost-effective drug development through the integration of imaging biomarkers into phase 1, 2, 3 and 4 therapeutics clinical trials. In addition, the workshop will explore key issues involved with imaging participation in multi-center trials.

January 14, 2009 - University of Ottawa Heart Institute (UOHI) researchers have successfully grown blood vessels in damaged muscle tissue by injecting a biomaterial developed specifically to attract new cells and support regeneration.

Blood vessel regeneration suggests that the body's own cells might one day be used to repair heart damage and restore function.

Details of the regeneration process are published online in the Journal of the Federation of American Societies for Experimental Biology (http://www.fasebj.org/cgi/content/abstract/fj.08-111054v1).

January 13, 2009 - Vital Images Inc. and Toshiba Medical Systems Corp. have agreed to collaborate on a joint investment to develop and deliver innovative technology advancements for Toshiba's modalities, including the Aquilion ONE CT scanner, and Vital Images' advanced visualization software solutions.

January 13, 2009 -W.L. Gore and Associates today said it received CE Mark of its GORE VIABAHN Endoprosthesis with PROPATEN Bioactive Surface in the European Union.

The GORE VIABAHN Endoprosthesis with PROPATEN Bioactive Surface combines Gore’s propriety heparin surface with the performance of the GORE VIABAHN Endoprosthesis for the treatment of arterial vascular disease. The GORE VIABAHN Endoprosthesis is indicated for the endovascular grafting of peripheral arteries.

January 13, 2009 - Edwards Lifesciences Corp. said Jan. 9 the Patents Court in the United Kingdom upheld the validity of Edwards’ U.K. Andersen patent for transcatheter valve technology and had CoreValve Inc.’s invalidity claims dismissed on all grounds.

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now